CDER Deputy Galson Will Run Drug Center For At Least Six Months
This article was originally published in The Tan Sheet
Executive Summary
Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, will be acting center director during the period when FDA is expected to announce a decision on forced Rx-to-OTC switches
You may also be interested in...
FDA Commissioner Confirmation Clears The Way For Personnel Changes
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency
FDA Awaits Word On Commissioner McClellan; Is He Headed To CMS?
The public speculation about FDA Commissioner McClellan's next move within the Bush Administration indicates the importance of the Medicare prescription drug bill to the White House heading into the November elections
FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding
The Medicare prescription drug coverage legislation should help FDA make the case for additional funding for post-marketing surveillance, according to Center for Drug Evaluation & Research Acting Director Steven Galson, MD